

06-13-00

A
Box 59Please type a plus (+) inside this box - ☒

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

7760-012

Total Pages

44

First Named Inventor or Application Identifier

Marchalonis et al.

Express Mail Label No.

EL 501 632 634 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☒ Specification, including a Table of Contents [Total Pages 38]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description of the Invention (including drawings, if filed)
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC 113) [Total Sheets]
4. ☒ Oath or Declaration [Total Sheets 2]
 - a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTORS(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: filed .

18. CORRESPONDENCE ADDRESS☒ Customer Number or Bar Code Label

20583

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME					
ADDRESS					
CITY		STATE		ZIP CODE	
COUNTRY		TELEPHONE		FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Marchalonis et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: MODULATION OF IMMUNE
RESPONSE AND METHODS
BASED THEREON

Attorney Docket No.: 7760-012



TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: June 12, 2000

by: *Walter Dummer*
Thomas E. Friebe
Thomas E. Friebe
REG. NO. 40,203
29,258
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

MODULATION OF IMMUNE RESPONSE AND METHODS BASED THEREON

1.	FIELD OF THE INVENTION	1
2.	BACKGROUND OF THE INVENTION	1
3.	SUMMARY OF THE INVENTION	2
4.	DETAILED DESCRIPTION OF THE INVENTION	10
4.1	PEPTIDE AND PEPTIDE DERIVATIVES	10
4.2	COMPOSITIONS OF AND METHODS FOR USE OF THE PEPTIDES AND PEPTIDE DERIVATIVES	14

MODULATION OF IMMUNE RESPONSE AND METHODS BASED THEREON

1. FIELD OF THE INVENTION

The present invention relates to methods for the prevention and/or treatment
5 of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-positive human, by administering a peptide derived from T-cell receptors, or a derivative of the peptide. The present invention also relates to peptides derived from T-cell receptors, and derivatives of such peptides, which are useful in such methods.

10

2. BACKGROUND OF THE INVENTION

The immune response is a complex and dynamic process initiated by infection, autoantigens, tumor-associated antigens and transplantation that involves antigen presenting cells (macrophages or dendritic cells), antigen-specific thymus-derived
15 lymphocytes (T-cells) that can be further discriminated into helper or cytotoxic T-cells, and antibody forming cells of the B cell lineage. The helper T cells can be further differentiated into subsets termed Th1 that produce mostly interferon- γ (IFN- γ), or interleukin-2 (IL-2), and Th2 cells that produce mainly interleukin-4 (IL-4) or interleukin-5 (IL-5). The Th1 cells function predominantly in inflammatory reactions, where they recruit macrophages
20 and other non-lymphoid cell types in the destruction of infectious agents. The Th2-type cells help principally in the production of antibodies through interactions with B cells, and this role predisposes to the development of asthma and allergic reactivity because of the generation of the reagenic antibody IgE (Wills-Karp, 1999, Ann. Rev. Immunol. 17:255-81).

25 The complex interactions among the distinct cell types are regulated by the secreted cytokines, and it is now recognized that functional balance between the two subsets of T-cells is important for normal immunity (Romagnani, 1997, Immunology Today 18: 263-266; Infante-Duarte et al., 1999, Immunopathol. 21:317-338). The definition of Th1 and Th2 helper T cells is an operational one based on expression of cytokines considered
30 characteristic of the individual subsets, although non-lymphoid cells can produce certain essential cytokines. Often, both Th1 and Th2 responses are ongoing in particular infections, especially at later stages. Th1-type responses are generally protective against intracellular parasites; whereas extra cellular parasites are better counteracted by so-called Th0 T-cells producing both Th1 and Th2 cytokines, thus generating both cellular and humoral
35 immunity. Optimal protection against metazoan parasites such as helminths is apparently conferred by Th2 responses. Th2-type responses favor HIV progression by allowing

enhanced HIV replication in CD4⁺ T-cells, and a strong imbalance between Th1 and Th2-type cytokine production is observed in mice infected with defective leukemia virus, the so-called MAIDS model (Watson et al., 1995, J. Immunol. 155:2282-2291; U.S. Patent No. 5,911,990 to Marchalonis et al.).

5 Polarized or unbalanced allergen-specific Th2 responses are responsible for initial triggering of allergic inflammation in atopic subjects. In general, polarization of Th1/Th2 cytokine expression induced by interaction of the pathogen with the host can lead to situations destructive to the host; *i.e.*, the Th1-Th2 shift in MAIDS. However, correction of the imbalance can restore beneficial protection to the infected animal. Th1-dependent
10 protection and Th2-mediated susceptibility is found in the response to the intracellular parasite *Leishmania*, and in leprosy, caused by *Mycobacterium leprae*.

Thus, it would be beneficial to have compositions and methods for maintaining proper immune system functioning, *i.e.*, proper amounts and ratios of cytokine production, in the presence of an underlying pathogenic condition. One molecule that
15 provides for the proper functioning of the immune system and suppression of progression to AIDS in an immunodeficiency-type retrovirus-infected individual is described in U.S. Patent No. 5,911,990 to Marchalonis et al. The molecule is a peptide that is derived from the T cell-receptor and has the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1). This peptide was shown to suppress
20 progression to AIDS and normalize aberrant Th1 and Th2 cytokine production in individuals infected with an immunodeficiency-type retrovirus.

Citation of a reference in this or in any section of the specification shall not be construed as an admission that such reference is prior art to the present invention.

25 3. SUMMARY OF THE INVENTION

The present invention is directed to a T-cell receptor (TCR)-derived peptide, or a derivative of the peptide, and methods for their use. The TCR-derived peptide of the present invention is selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID
30 NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID
35 NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID

NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15).

The present invention is also directed to a derivative of the foregoing peptides of SEQ ID NOS:1-15. Such derivative peptides include those in which one or more amino acid residue has been replaced by a similar amino acid, residue, or the corresponding D-isomer, or by a non-naturally occurring amino acid residue. Other derivative peptides include cyclic derivatives of the peptides and chemical derivatives of the peptides of SEQ ID NOS:1-15. Other derivatives also include dual peptides or multimer peptides consisting of the same or of different peptides of SEQ ID NOS:1-15, wherein the peptides are covalently linked to one another directly or through a spacer. Other derivatives include those peptides which have insertions or deletions relative to the peptides of SEQ ID NOS:1-15.

The present invention is also directed to pharmaceutical compositions comprising a peptide of the present invention, or a derivative thereof, and a pharmaceutically acceptable carrier. The pharmaceutical compositions are used, *e.g.*, as promoters of Th1 cytokine production and/or inhibitors of Th2 cytokine production in an individual animal, preferably a mammal, including a human.

The present invention is also directed to methods for the use of a T-cell receptor derived peptide, or a derivative thereof, to increase production of at least one Th1 cytokine and/or decrease production of at least one Th2 cytokine, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID

NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual, in an amount sufficient to increase production of at least one Th1 cytokine and/or decrease production of at least one Th2 cytokine.

The present invention is also directed to methods for increasing production of at least one Th1 cytokine or decreasing production of at least one Th2 cytokine in an individual free of infection with an immunodeficiency-type retrovirus comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual free of infection with an immunodeficiency-type retrovirus in an amount sufficient to increase production of at least one Th1 cytokine or decrease production of at least one Th2 cytokine.

The present invention is also directed to methods for the use of a peptide or a derivative thereof for the prevention of progression to, or delay the onset of, AIDS in an immunodeficiency-type retrovirus infected individual, *e.g.*, an HIV-infected human, comprising administering a peptide selected from the group consisting of peptides

comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an immunodeficiency-type retrovirus infected individual, in an amount sufficient to arrest the development of immune dysfunction or cytokine dysregulation, which allows such retrovirus infections to immunologically weaken the host, *i.e.*, to prevent progression to, or delay the onset of, AIDS.

The present invention also provides methods for reversing the deleterious effects of infection with an immunodeficiency-type retrovirus, *e.g.*, HIV, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID

NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual infected with an immunodeficiency-type retrovirus, in an amount
5 sufficient to reverse the deleterious effects of immunodeficiency-type retrovirus infection.

Methods of suppressing progression to immune dysfunction and cytokine dysregulation caused by HIV infection in an individual are also provided in the present invention, said method comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn
10 Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp
15 Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp
20 Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ
25 ID NO:15), or a derivative thereof, to an individual infected with HIV in an amount sufficient to suppress or delay progression to immune dysfunction and cytokine dysregulation.

Moreover, methods for preventing immunosuppression and cytokine dysregulation induced by infection with an immunodeficiency-type retrovirus are also
30 provided in the present invention, said method comprising administering to an individual infected with an immunodeficiency-type retrovirus a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp
35 Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln

Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp
Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp
Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile
Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe
5 Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu
Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp
Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly
Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr
Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp
10 Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any
amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ
ID NO:15), or a derivative thereof, in an amount sufficient to prevent immunosuppression
and cytokine dysregulation induced by infection with an immunodeficiency-type retrovirus.

The present invention is also directed to methods for the prevention and/or
15 treatment of a disease or disorder of the cardiovascular system, comprising administering a
peptide selected from the group consisting of peptides comprising the amino acid sequence
Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala
Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys
Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile
20 Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu
Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val
Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile
Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile
Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser
25 Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser
Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile
Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr
Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly
Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr
30 Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly
Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other
charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual in
need thereof, in an amount sufficient to prevent or treat a disease or disorder of the
cardiovascular system.

35 Illustrative disease and disorders of the cardiovascular system which can be
ameliorated, prevented or treated according to the present invention include, but are not

limited to, atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, thrombus formation, and retrovirus-induced cardiovascular dysfunction.

The present invention is also directed to methods for the prevention and/or
5 treatment of an allergic disease or disorder characterized by increased IgE production, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu
10 Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
15 Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val
20 (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual in need thereof, in an amount sufficient to prevent or treat an allergic disease or disorder in which the disease or disorder is characterized by
25 increased IgE production.

Illustrative examples of such allergic diseases and disorders characterized by increased IgE production include, but are not limited to, allergy, asthma, delayed hypersensitivity, septic shock, and anaphylactic shock.

The present invention is also directed to methods for inhibiting the growth of
30 a solid tumor or reducing the volume of a solid tumor, comprising administering a peptide selected from the group consisting of peptide comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln
35 Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser

Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual in need thereof, in an amount sufficient to inhibit the growth of, or reduce the volume of, the solid tumor.

Solid tumors include, but are not limited to sarcomas, carcinomas, lymphomas or other solid tumor cancers, such as germ line tumors and tumors of the central nervous system, including, but not limited to, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer, liver cancer, colon cancer, and melanoma.

The present invention also provides methods for preventing immunosuppression or suppressing progression to immune dysfunction or cytokine dysregulation in an individual infected with a viral, fungal or bacterial infectious agent other than an immunodeficiency-type retrovirus, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly

Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, in an amount sufficient for preventing immunosuppression or suppressing progression to immune dysfunction or cytokine dysregulation in an individual infected with a viral, fungal or bacterial infectious agent other than an immunodeficiency-type retrovirus.

4. DETAILED DESCRIPTION OF THE INVENTION

4.1 PEPTIDE AND PEPTIDE DERIVATIVES

The peptides, peptide derivatives and pharmaceutical compositions of the present invention can increase production of at least one Th1 cytokine and/or decrease production of at least one Th2 cytokine, *e.g.*, in an individual, in cell culture. The peptides and compositions have anti-immune activity, *i.e.*, inhibitory effects against IgE production. The peptides and compositions also inhibit the progression to AIDS in an immunodeficiency-type retrovirus-infected individual, as well as the ability to inhibit the growth of a solid tumor or the ability to reduce the volume of a solid tumor. The peptides and compositions also can treat or prevent cardiovascular diseases or disorders. As used herein, treating or preventing a disease or disorder also encompasses ameliorating at least one symptom of such disease or disorder.

In certain embodiments, the term "purified" is used to indicate that the peptide or peptide derivative is substantially free of foreign components, such as bacterial proteins or cellular debris, with which it is normally associated as a part of its production. In a preferred embodiment, substantially free indicates that at least 75% of the foreign components have been removed. In more preferred embodiment, at least 95% of the foreign components have been removed. In other certain embodiments, "purified" indicates that the peptide or peptide derivative is 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% of the total protein of a composition.

As used herein, the term "peptide" refers to molecules having no more than 250 amino acids. In certain embodiments, the peptide has about 5 to about 200 amino acids. In other embodiments, the peptide has about 10 to about 100 amino acids. In certain preferred embodiments, the peptide has about 5 to about 25 amino acids. In yet more preferred embodiments, the peptide has about 5 to about 20 amino acids.

As used herein, the term "peptide derivative" includes cyclic peptides; peptides obtained by substitution of a natural amino acid residue by a similar amino acid, the corresponding D-stereomer, or by a non-natural amino acid residue; chemical derivatives of the peptides; dual peptides; and multimers of the peptides. The term also

includes those peptide that have a deletion or insertion relative to the amino acid sequence of SEQ ID NOS:1-15. For example, a derivative of the peptides of SEQ ID NOS:3-11 is in which the 5'-most leucine residue is not present.

The term "cyclic peptides" as used herein are cyclic derivatives of the peptides of SEQ ID NOS:1-15 to which two additional amino acid residues suitable for cyclization have been added, one at the carboxyl terminus and one at the amino terminus. Thus, the cyclic peptides contain either an intramolecular disulfide bond, *i.e.*, -S-S-, an intramolecular amide bond between the two added residues, *i.e.*, -CONH- or -NHCO- or intramolecular S-alkyl bonds, *i.e.*, -S-(CH₂)_n-CONH- or -NH-CO(CH₂)_n-S-, wherein n is 1 or 2. In a preferred embodiment, the peptide Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1) is derivatized by the incorporation of two terminal cysteine residues and cyclized through an intramolecular S-S bond between the two incorporated cysteine residues. In yet another preferred embodiment, the peptide Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val (SEQ ID NO:2) is derivatized by the incorporation of two terminal cysteine residues and cyclized through an intramolecular S-S bond between the two incorporated cysteine residues.

The cyclic derivatives containing an intramolecular disulfide bond may be prepared by conventional solid phase synthesis (Merrifield et al., 1982) while incorporating suitable S-protected cysteine or homocysteine residues at the positions selected for cyclization such as the amino and carboxyl termini (Sahm et al., 1996, J. Pharm. Pharmacol. 48(2):197). Following completion of the chain assembly, cyclization can be performed either by selective removal of the S- protecting groups with a consequent on-support oxidation of the two free corresponding SH-functions, to form S-S bonds, followed by conventional removal of the product from the support and appropriate purification procedure, or by removal of the peptide from the support along with complete side-chain deprotection, followed by oxidation of the free SH-functions in highly dilute aqueous solution.

The cyclic derivatives containing an intramolecular amide bond may be prepared by conventional solid phase synthesis while incorporating suitable amino and carboxyl side-chain protected amino acid derivatives at the positions selected for cyclization. The cyclic derivatives containing intramolecular -S-alkyl bonds can be prepared by conventional solid phase synthesis while incorporating an amino acid residue with a suitable amino-protected side chain, and a suitable S- protected cysteine or homocysteine residue at the positions selected for cyclization.

According to another embodiment, a peptide of the invention has one or more of the amino acid residues replaced by the corresponding D-amino acid residue. Thus

the peptide or peptide derivative of the invention may be all-L, all-D or a D,L- peptide. In another embodiment, an amino acid residue may be replaced by a non-natural amino acid residue provided that the charge of the peptide is not substantially changed. Examples of non-naturally occurring or derivatized non-naturally occurring amino acids include N α -methyl amino acids, C α -methyl amino acids, β -methyl amino acids and amino acid analogs in general such as, but not being limited to, β -alanine (β -Ala), norvaline (Nva), norleucine (Nle), 4-aminobutyric acid (γ -Abu), 2-aminoisobutyric acid (Aib), 6-aminohexanoic acid (ϵ -Ahx), ornithine (Orn), hydroxyproline (Hyp), sarcosine, citrulline, cysteic acid, and cyclohexylalanine. In yet another embodiment of the present invention, one or more amino acid residues can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A chemical derivative of a peptide of SEQ ID NOS:1-15 includes, but is not limited to, a derivative containing additional chemical moieties not normally a part of the peptide provided that the derivative retains a function of the peptide. Examples of such derivatives are: (a) N-acyl derivatives of the amino terminal or of another free amino group, wherein the acyl group may be either an alkanoyl group, *e.g.*, acetyl, hexanoyl, octanoyl; an aroyl group, *e.g.*, benzoyl, or a blocking group such as Fmoc (fluorenylmethyl-O-CO-), carbobenzoxy (benzyl-O-CO-), monomethoxysuccinyl, naphthyl-NH-CO-, acetylamino-caproyl, adamantyl-NH-CO-; (b) esters of the carboxyl terminal or of another free carboxyl or hydroxy groups; (c) amides of the carboxyl terminal or of another free carboxyl groups produced by reaction with ammonia or with a suitable amine; (d) glycosylated derivatives; (e) phosphorylated derivatives; (f) derivatives conjugated to lipophilic moieties, *e.g.*, caproyl, lauryl, stearoyl; and (g) derivatives conjugated to an antibody or other cellular ligands.

Also included among the chemical derivatives are those derivatives obtained by modification of the peptide bond -CO-NH-, for example, by (a) reduction to -CH₂-NH-; (b) alkylation to -CO-N (alkyl)-; (c) inversion to -NH-CO-.

A dual peptide according to the invention consists of two the same or different peptides of the invention covalently linked to one another or through a spacer such

as by a short stretch of alanine residues or by a putative site for proteolysis by cathepsin (see U.S. Patent No. 5,126,249 and European Patent No. 495,049 with respect to such sites). This will induce site-specific proteolysis of the preferred form into the two desired analogues. In one embodiment the dual peptide is Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:16).

Multimers according to the invention consist of polymer molecules formed from a number of the same or different peptides or derivatives thereof. The polymerization is carried out with a suitable polymerization agent, such as 0.1% glutaraldehyde (Audibert et al., 1981, Nature 289:593).

In one aspect of the invention, the peptide derivative is more resistant to proteolytic degradation than the corresponding nonderivatized peptide. For example, a peptide derivative having D-amino acid substitution(s) in place of a L-amino acid resists proteolytic cleavage when administered to a mammal. In another aspect of the invention, the peptide derivative has increased permeability across a cell membrane than the corresponding nonderivatized peptide, *e.g.*, those peptide derivatives having a lipophilic moiety coupled at the amino and/or carboxyl terminus. In yet another aspect, the peptide derivative has enhanced biological activity, *e.g.*, those peptide derivatives which are dualized or multimerized peptides.

The peptides or peptide derivatives of the present invention are obtained by any method of peptide synthesis known to those of skill in the art, including synthetic and recombinant techniques. For example, the peptides or peptide derivatives can be obtained by solid phase peptide synthesis, which, in brief, consists of coupling the carboxyl group of the C-terminal amino acid to a resin and successively adding N-alpha protected amino acids. The protecting groups may be any known in the art. Before each new amino acid is added to the growing chain, the protecting group of the previous amino acid added to the chain is removed. The coupling of amino acids to appropriate resins is described by Rivier et al., U.S. Patent No. 4,244,946. Such solid phase syntheses have been described, for example, by Merrifield, 1964, *J. Am. Chem. Soc.* 85:2149; Vale et al. 1981, *Science* 213:1394-1397; Marki et al., 1981 *J. Am. Chem. Soc.* 103:3178 and in U.S. Patent Nos. 4,305,872 and 4,316,891. In a preferred aspect, an automated peptide synthesizer is employed.

Purification of the synthesized peptides or peptide derivatives is carried out by standard methods including chromatography (*e.g.*, ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, hydrophobicity, or by any other standard technique for the purification of proteins. In a preferred embodiment, thin

layer chromatography is employed. In yet another preferred embodiment, high performance liquid chromatography (HPLC) under reverse phase conditions is employed to purify a peptide or peptide derivative of the present invention.

5 **4.2 COMPOSITIONS OF AND METHODS FOR USE OF THE
 PEPTIDES AND PEPTIDE DERIVATIVES**

 The present invention provides methods for modulating the immune response in an individual, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn
10 Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp
15 Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp
20 Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ
25 ID NO:15), or a derivative thereof, to an individual in an amount sufficient to increase production of at least one Th1 cytokine, such as interleukin 2 and interferon- γ , and/or decrease production of at least one Th2 cytokine, such as interleukin-4, interleukin 5, interleukin 6, interleukin 10, and immunoglobulin G.

 In one embodiment, the present invention is directed to methods for
30 increasing production of at least one Th1 cytokine or decreasing production of at least one Th2 cytokine in an individual free of infection with an immunodeficiency-type retrovirus comprising administering an effective amount of a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser
35 Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp

Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile
5 Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr
10 Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual free of infection with an immunodeficiency-type retrovirus in an amount sufficient to increase production of at least
15 one Th1 cytokine or decrease production of at least one Th2 cytokine.

In one embodiment, the present invention provides methods for delaying progression to AIDS, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual infected with an immunodeficiency-type retrovirus in an amount sufficient to delay the progression to AIDS.

Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr
Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp
Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any
amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ
5 ID NO:15), or a derivative thereof, in an individual infected with HIV in an amount
sufficient to suppress progression to immune dysfunction and cytokine dysregulation.

Moreover, methods of preventing immunosuppression induced by infection
with an immunodeficiency-type retrovirus are provided by the present invention, said
method comprising administering a peptide selected from the group consisting of peptides
10 comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr
Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr
Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu
Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu
Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu
15 Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr
Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr
Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
20 Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr
Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val
Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val
(SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val
(SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and
25 Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a
derivative thereof, to an individual infected with an immunodeficiency-type retrovirus in an
amount sufficient to prevent immunosuppression.

In yet another embodiment of the present invention, methods are provided for
the prevention and/or treatment of a disease or disorder of the cardiovascular system,

30 comprising administering a peptide selected from the group consisting of peptides
comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr
Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr
Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu
Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu
35 Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu
Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr

Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr
Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
5 Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr
Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val
Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val
(SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val
(SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and
10 Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a
derivative thereof, to an individual in need thereof, in an amount sufficient to prevent or
treat a disease or disorder of the cardiovascular system. Illustrative disease and disorders of
the cardiovascular system which can be ameliorated, prevented or treated according to the
present invention include, but are not limited to, atherosclerosis, arteriosclerosis,
15 atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction,
thrombus formation, and retrovirus-induced cardiovascular dysfunction.

In yet another embodiment, the present invention is directed to methods for
the prevention and/or treatment of an allergic disease or disorder characterized by increased
IgE production, comprising administering a peptide selected from the group consisting of
20 peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe
Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg
Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val
Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val
Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met
25 Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp
Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp
Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr
Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr
Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr
30 Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr
Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu
Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr
Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val
Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid
35 and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15),
or a derivative thereof, to an individual in need thereof, in an amount sufficient to prevent or

1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85
87
89
91
93
95
97
99
101
103
105
107
109
111
113
115
117
119
121
123
125
127
129
131
133
135
137
139
141
143
145
147
149
151
153
155
157
159
161
163
165
167
169
171
173
175
177
179
181
183
185
187
189
191
193
195
197
199
201
203
205
207
209
211
213
215
217
219
221
223
225
227
229
231
233
235
237
239
241
243
245
247
249
251
253
255
257
259
261
263
265
267
269
271
273
275
277
279
281
283
285
287
289
291
293
295
297
299
301
303
305
307
309
311
313
315
317
319
321
323
325
327
329
331
333
335
337
339
341
343
345
347
349
351
353
355
357
359
361
363
365
367
369
371
373
375
377
379
381
383
385
387
389
391
393
395
397
399
401
403
405
407
409
411
413
415
417
419
421
423
425
427
429
431
433
435
437
439
441
443
445
447
449
451
453
455
457
459
461
463
465
467
469
471
473
475
477
479
481
483
485
487
489
491
493
495
497
499
501
503
505
507
509
511
513
515
517
519
521
523
525
527
529
531
533
535
537
539
541
543
545
547
549
551
553
555
557
559
561
563
565
567
569
571
573
575
577
579
581
583
585
587
589
591
593
595
597
599
601
603
605
607
609
611
613
615
617
619
621
623
625
627
629
631
633
635
637
639
641
643
645
647
649
651
653
655
657
659
661
663
665
667
669
671
673
675
677
679
681
683
685
687
689
691
693
695
697
699
701
703
705
707
709
711
713
715
717
719
721
723
725
727
729
731
733
735
737
739
741
743
745
747
749
751
753
755
757
759
761
763
765
767
769
771
773
775
777
779
781
783
785
787
789
791
793
795
797
799
801
803
805
807
809
811
813
815
817
819
821
823
825
827
829
831
833
835
837
839
841
843
845
847
849
851
853
855
857
859
861
863
865
867
869
871
873
875
877
879
881
883
885
887
889
891
893
895
897
899
901
903
905
907
909
911
913
915
917
919
921
923
925
927
929
931
933
935
937
939
941
943
945
947
949
951
953
955
957
959
961
963
965
967
969
971
973
975
977
979
981
983
985
987
989
991
993
995
997
999

treat an allergic disease or disorder, in which the disease or disorder is characterized by increased IgE production. Illustrative examples of such allergic diseases and disorders characterized by increased IgE production include, but are not limited to, allergy, asthma, delayed hypersensitivity, septic shock, and anaphylactic shock.

5 In yet another embodiment, the present invention is also directed to methods for inhibiting the growth of a solid tumor or reducing the volume of a solid tumor, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr
10 Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr
15 Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val
20 Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual having a solid tumor, in an amount sufficient to inhibit
25 the growth of, or reduce the volume of, the solid tumor. Solid tumors include, but are not limited to sarcomas, carcinomas, lymphomas or other solid tumor cancers, such as germ line tumors and tumors of the central nervous system, including, but not limited to, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer,
30 liver cancer, colon cancer, and melanoma.

The present invention also provides methods for preventing immunosuppression or suppressing progression to immune dysfunction or cytokine dysregulation in an individual infected with a viral, fungal or bacterial infectious agent other than an immunodeficiency-type retrovirus, comprising administering a peptide selected
35 from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr

Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser
Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr
Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu
5 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu
Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu
Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu
Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val
10 Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr
Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe
Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly
Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa,
wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino
15 acid molecule (SEQ ID NO:15), or a derivative thereof, in an amount sufficient for
preventing immunosuppression or suppressing progression to immune dysfunction or
cytokine dysregulation in an individual infected with a viral, fungal or bacterial infectious
agent other than an immunodeficiency-type retrovirus.

The individual administered a peptide or peptide derivative of the present invention is an animal, including but not limited to animals such as cows, sheep, pigs, chickens, etc., preferably a mammal, and most preferably a human. Moreover, the individual may or may not be infected with an infectious agent, *e.g.*, viral, fungal, bacterial, which infection results in immune dysfunction or cytokine dysregulation, *e.g.*, infection with an immunodeficiency-type retrovirus.

compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention systemically, *e.g.*, via the blood stream. In yet another specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant solid tumor.

In another embodiment, the Therapeutic can be delivered in a vesicle, in particular a liposome (*see* Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see* generally *ibid.*)

In yet another embodiment, the Therapeutic can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (*see* *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); *see also* Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, *i.e.*, the brain, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in *Medical Applications of Controlled Release, supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the Therapeutic is a nucleic acid encoding a peptide or peptide derivative of the present invention, the nucleic acid can be administered *in vivo* to promote expression of its encoded peptide or derivative, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see *e.g.*, Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868), etc. Alternatively, a nucleic acid Therapeutic can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a peptide or peptide derivative of the present invention ("Therapeutic"), and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified

form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The Therapeutics can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The compositions can also contain an adjuvant such as alum, Freund's complete or incomplete adjuvants, poly (AU) or RIBI adjuvant, or coupled to a carrier such as albumin, ovalbumin, or other native or engineered protein.

The present invention also provides for the modification of the peptide or peptide derivative such that it is more stable once administered to an individual, *i.e.*, once administered it has a longer time period of effectiveness as compared to unmodified peptide. Such modifications are well known to those of skill in the art, *e.g.*, polyethylene glycol derivatization (PEGylation), microencapsulation, etc.

The amount of the Therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges, *e.g.*, assays measuring the effect of a Therapeutic on Th1 or Th2 cytokine production in cell culture. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However,

5 suitable dosage ranges for intravenous administration are generally about 1-1000 micrograms of active compound per kilogram body weight, more preferably about 5-500 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. Moreover, the compositions can be administered in multiple doses over a period of time.

10 In one illustrative embodiment, doses of 5 mg/kg of body weight to 25 mg/kg of body weight of the peptide comprising the sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1) in saline are administered in divided doses following infection with an immunodeficiency-type retrovirus. Preferably, doses of approximately 10 mg/kg of body weight to 25 mg/kg of body weight of the peptide of SEQ ID NO:1 in saline are administered in divided doses. Most preferably, doses of 10 mg/kg of body weight are administered. Multiple doses administered approximately once per month increase the efficacy of the peptide therapy. Dosage amounts, however, may vary depending on the route of administration and depending on whether the peptide is administered with or without adjuvant.

15 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

20 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

25 Various publications are cited herein, the disclosures of which are incorporated by reference herein in their entirety.

30

35

WHAT IS CLAIMED IS:

1. A purified peptide selected from the group consisting of peptides comprising the amino acid sequence Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val
5 Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val
Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met
Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp
Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp
Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr
10 Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr
Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr
Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr
Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu
Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr
15 Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val
Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid
and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15).

2. A purified peptide consisting of the amino acid sequence Ala Asn Tyr
20 Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2).

3. A purified derivative of the peptide according to claim 1 or 2.

4. A purified derivative of a peptide consisting of the sequence Cys Lys Pro
25 Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1).

5. A pharmaceutical composition comprising a peptide or peptide derivative
according to claim 1, 2, 3 or 4 and a pharmaceutically acceptable carrier.

30 6. A method to increase production of at least one Th1 cytokine or to
decrease production of at least one Th2 cytokine comprising administering an effective
amount of a peptide selected from the group consisting of peptides comprising the amino
acid sequence Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID
NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID
35 NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID
NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID

NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual in an amount sufficient to increase production of at least one Th1 cytokine or decrease production of at least one Th2 cytokine.

7. A method to increase production of at least one Th1 cytokine or to decrease production of at least one Th2 cytokine in an individual free of infection with an immunodeficiency-type retrovirus comprising administering an effective amount of a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual free of infection with an immunodeficiency-type retrovirus in an amount sufficient to increase production of at least one Th1 cytokine or decrease production of at least one Th2 cytokine.

8. A method of delaying the onset of AIDS, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu
 5 Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr
 10 Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly
 15 Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual infected with an immunodeficiency-type retrovirus in an amount sufficient to delay the onset of AIDS.

20

9. The method according to claim 8, wherein the immunodeficiency-type retrovirus is HIV and the individual is a human.

10. The method according to claim 8, wherein the immunodeficiency-type
 25 retrovirus is feline immunodeficiency virus.

11. A method of delaying the onset of AIDS, comprising administering a derivative of a peptide comprising the sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1) to an individual infected with an
 30 immunodeficiency-type retrovirus in an amount sufficient to delay the onset of AIDS.

12. The method according to claim 11, wherein the immunodeficiency-type retrovirus is HIV and the individual is a human.

13. The method according to claim 11, wherein the immunodeficiency-type
 35 retrovirus is feline immunodeficiency virus.

14. A method for reversing the deleterious effects of infection with an immunodeficiency-type retrovirus, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu
5 Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln
10 Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly
15 Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual infected with an immunodeficiency-type retrovirus in an amount sufficient to reverse the deleterious effects
20 of infection with an immunodeficiency-type retrovirus.

15. The method according to claim 14, wherein the immunodeficiency-type retrovirus is HIV and the individual is a human.

25 16. A method for the prevention or treatment of a disease or disorder of the cardiovascular system, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp
30 Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile
35 Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu

Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp
5 Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual in an amount sufficient to treat or prevent a disease or disorder of the cardiovascular system.

10 17. The method according to claim 16 wherein the disease or disorder is selected from the group consisting of atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, thrombus formation, and retrovirus-induced cardiovascular dysfunction.

15 18. A method for the prevention or treatment of an allergic disease or disorder characterized by increased IgE production, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln
20 Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser
25 Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr
30 Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual in an amount sufficient to treat or prevent an allergic disease or disorder characterized by
35 increased IgE production.

19. The method according to claim 18 wherein said allergic disease or disorder characterized by increased IgE production is selected from the group consisting of allergy, asthma, delayed hypersensitivity, septic shock, and anaphylactic shock.

5 20. A method for inhibiting the growth of a solid tumor or reducing the volume of a solid tumor, comprising administering a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp
10 Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile
15 Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr
20 Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual with a solid tumor in an amount sufficient to inhibit the growth of the solid tumor or to reduce the volume of the solid
25 tumor.

21. The method according to claim 20 wherein the solid tumor is selected from the group consisting of sarcomas, carcinomas, lymphomas and other solid tumor cancers.

30

22. The method according to claim 21 wherein the solid tumor is a tumor of the germ line or is a tumor of the central nervous system, or is a breast cancer tumor, prostate cancer tumor, cervical cancer tumor, uterine cancer tumor, lung cancer tumor, ovarian cancer tumor, testicular cancer tumor, thyroid cancer tumor, astrocytoma, glioma,
35 pancreatic cancer tumor, stomach cancer tumor, liver cancer tumor, colon cancer tumor, or a melanoma tumor.

23. A method for preventing immunosuppression or suppressing progression to immune dysfunction or cytokine dysregulation in an individual infected with a viral, fungal or bacterial infectious agent other than an immunodeficiency-type retrovirus, comprising administering a peptide selected from the group consisting of peptides

5 comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu
10 Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
15 Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), and Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and
20 Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof, to an individual infected with a viral, fungal or bacterial infectious agent in an amount sufficient to prevent immunosuppression or suppress progression to immune dysfunction or cytokine dysregulation in the infected individual.

24. The method according to claim 6 or 7 in which the Th1 cytokine is selected from the group consisting of interleukin 2 and interferon- γ .

25. The method according to claim 6 or 7 in which the Th2 cytokine is selected from the group consisting of interleukin-4, interleukin 5, interleukin 6, interleukin
30 10 and immunoglobulin G.

ABSTRACT

The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived from T cell receptors, or a derivative thereof. The present invention also relates to peptides derived from T-cell receptors, and derivatives thereof, which are useful in such methods. The peptides are selected from the group consisting of Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

MODULATION OF IMMUNE RESPONSE AND METHODS BASED THEREON

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on *(if applicable)*
☐ was filed in the United States on as Application No. *(for declaration not accompanying application)*
 with amendment(s) filed on *(if applicable)*
☐ was filed as PCT international Application No. on and was amended under PCT Article 19 on *(if applicable)*

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE




I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:		PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N.Y. 10036-2711		DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS LLP DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME MARCHALONIS	FIRST NAME JOHN	MIDDLE NAME J.	
	RESIDENCE & CITIZENSHIP	CITY TUCSON	STATE OR FOREIGN COUNTRY ARIZONA	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 5661 N. CAMINO ARTURO	CITY TUCSON	STATE OR COUNTRY ARIZONA	ZIP CODE 85718
202	FULL NAME OF INVENTOR	LAST NAME WATSON	FIRST NAME RONALD	MIDDLE NAME R.	
	RESIDENCE & CITIZENSHIP	CITY TUCSON	STATE OR FOREIGN COUNTRY ARIZONA	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 4703 N. CITYVIEW DRIVE	CITY TUCSON	STATE OR COUNTRY ARIZONA	ZIP CODE 85749
203	FULL NAME OF INVENTOR	LAST NAME SCHLUTER	FIRST NAME SAMUEL	MIDDLE NAME F.	
	RESIDENCE & CITIZENSHIP	CITY TUCSON	STATE OR FOREIGN COUNTRY ARIZONA	COUNTRY OF CITIZENSHIP AUSTRALIA	
	POST OFFICE ADDRESS	STREET 2300 W. INA, #2302	CITY TUCSON	STATE OR COUNTRY ARIZONA	ZIP CODE 85741

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201  JOHN J. MARCHALONIS	SIGNATURE OF INVENTOR 202  RONALD R. WATSON	SIGNATURE OF INVENTOR 203  SAMUEL F. SCHLUTER
DATE June 2, 2000	DATE 2 June 2000	DATE June 2nd. 2000

SEQUENCE LISTING

<110> Marchalonis, John
Watson, Ronald
Schluter, Samuel

<120> MODULATION OF IMMUNE RESPONSE AND METHODS BASED THEREON

<130> 7760-012

<140>

<141>

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 1

Cys	Lys	Pro	Ile	Ser	Gly	His	Asn	Ser	Leu	Phe	Trp	Tyr	Arg	Gln	Thr
1				5					10					15	

<210> 2

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 2

Ala	Asn	Tyr	Gly	Tyr	Thr	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Thr	Val	Val
1				5					10					15	

<210> 3

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 3

Leu	Lys	Ile	Gln	Pro	Ser	Glu	Pro	Arg	Asp	Ser	Ala	Val	Tyr	Leu	Cys
1				5					10					15	

Ala

<210> 4
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 4
Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys
1 5 10 15

Ala

<210> 5
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 5
Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys
1 5 10 15

Ala

<210> 6
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 6
Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys
1 5 10 15

Ser

<210> 7
<211> 17
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 7

Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
1 5 10 15

Ala

<210> 8

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 8

Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
1 5 10 15

Gln

<210> 9

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 9

Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
1 5 10 15

Gln

<210> 10

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 10

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
 1 5 10 15

Ser

<210> 11
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: T-cell
 receptor-derived peptide

<400> 11
 Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys
 1 5 10 15

Gln

<210> 12
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: T-cell
 receptor-derived peptide

<400> 12
 Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val
 1 5 10 15

<210> 13
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: T-cell
 receptor-derived peptide

<400> 13
 Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val
 1 5 10 15

<210> 14
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 14

Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val
1 5 10 15

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> SITE

<222> (4)

<223> Xaa=any amino acid

<220>

<221> SITE

<222> (7)

<223> Xaa=Arg, Lys, Asp, Glu, His, or other charged
amino acid molecule

<220>

<223> Description of Artificial Sequence: T-cell
receptor-derived peptide

<400> 15

Thr Phe Gly Xaa Gly Thr Xaa
1 5